High-dose chemo and stem cell transplant for brain lymphoma
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a combination of high-dose chemotherapy drugs (gemcitabine, busulfan, and thiotepa) followed by a stem cell transplant for people with primary central nervous system lymphoma. It aims to see if this treatment can improve outcomes for patients whose disease has responded to initial therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- Your lymphoma must have shrunk or disappeared after initial treatment (confirmed by MRI or PET scan).
- You must be in good enough health to handle high-dose chemotherapy (ECOG score 0-2).
- You must have no lymphoma found outside your brain or spinal cord.
- Your heart, lungs, kidney, and liver function must be within safe limits.
- You must not have active hepatitis B or C, HIV, or other uncontrolled infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy drugs to treat lymphoma that started in your brain. The goal is to see if this treatment helps without having to use whole-brain radiation.
This trial tests a new treatment combining CAR-T cell therapy with stem cell transplant and two targeted drugs for patients with a type of brain lymphoma called PCNSL that has come back or not responded to first-line treatment.
This trial tests a new combination of drugs (teniposide, a PD-1 checkpoint inhibitor, and selinexor) for people with relapsed or refractory primary central nervous system lymphoma. It aims to see if this three-drug approach can shrink tumors or slow the disease when previous treatments haven't worked.
This trial tests a combination of three drugs (rituximab, methotrexate, and orelabrutinib) plus a PD-1 inhibitor for newly diagnosed or relapsed central nervous system lymphoma. The goal is to see if this new combination can improve outcomes for patients with this rare type of lymphoma.
This trial tests a combination of three drugs (high-dose methotrexate, thiotepa, and zanubrutinib) for people who have just been diagnosed with primary central nervous system lymphoma (PCNSL). The goal is to see if this three-drug cocktail works better than standard treatments.
This trial tests a combination of two drugs, epcoritamab and ibrutinib, for people whose lymphoma has come back or not responded to treatment and has spread to the brain or spinal cord. The goal is to see if this combination can help control the disease.
Hear when a new Primary Central Nervous System Lymphoma (PCNSL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.